Skip to content
10-Q

Quarterly Report

ARS Pharmaceuticals, Inc. SPRY

0001193125-25-273111

← back to feed
Filed
Nov 10, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 6, 2025 98.85M sh
Shares Diluted Q3 2025 · Sep 30, 2025 98.81M sh
Shares Diluted Q3 2025 · Sep 30, 2025 98.41M sh
Shares Diluted Q3 2025 · Sep 30, 2024 97.03M sh
Shares Diluted Q3 2025 · Sep 30, 2024 96.78M sh
Capex Q3 2025 · Sep 30, 2025 $339K
Capex Q3 2025 · Sep 30, 2024 $261K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$127.38M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$28.46M
Long Term Debt Q3 2025 · Sep 30, 2025 $96.23M
Long Term Debt Q3 2025 · Dec 31, 2024 $0
Short Term Investments Q3 2025 · Sep 30, 2025 $228.65M
Short Term Investments Q3 2025 · Dec 31, 2024 $263.21M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $59.56M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $50.82M
Stockholders Equity Q3 2025 · Sep 30, 2025 $147.66M
Stockholders Equity Q3 2025 · Jun 30, 2025 $192.32M
Stockholders Equity Q3 2025 · Mar 31, 2025 $228.97M
Stockholders Equity Q3 2025 · Dec 31, 2024 $256.8M
Stockholders Equity Q3 2025 · Sep 30, 2024 $200.98M
Stockholders Equity Q3 2025 · Jun 30, 2024 $215.24M
Stockholders Equity Q3 2025 · Mar 31, 2024 $223.87M
Stockholders Equity Q3 2025 · Dec 31, 2023 $230.76M
Current Liabilities Q3 2025 · Sep 30, 2025 $50.88M
Current Liabilities Q3 2025 · Dec 31, 2024 $23.44M
Total Liabilities Q3 2025 · Sep 30, 2025 $225.15M
Total Liabilities Q3 2025 · Dec 31, 2024 $94.36M
Current Assets Q3 2025 · Sep 30, 2025 $338.86M
Current Assets Q3 2025 · Dec 31, 2024 $334.3M
Total Assets Q3 2025 · Sep 30, 2025 $372.8M
Total Assets Q3 2025 · Dec 31, 2024 $351.15M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.52
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.32
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.20
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.43
Eps Basic Q3 2025 · Sep 30, 2025 −$0.52
Eps Basic Q3 2025 · Sep 30, 2025 −$1.32
Eps Basic Q3 2025 · Sep 30, 2024 −$0.20
Eps Basic Q3 2025 · Sep 30, 2024 −$0.43
Sga Expense Q3 2025 · Sep 30, 2025 $74.75M
Sga Expense Q3 2025 · Sep 30, 2025 $170.17M
Sga Expense Q3 2025 · Sep 30, 2024 $19.28M
Sga Expense Q3 2025 · Sep 30, 2024 $36.18M
Rd Expense Q3 2025 · Sep 30, 2025 $2.75M
Rd Expense Q3 2025 · Sep 30, 2025 $9.74M
Rd Expense Q3 2025 · Sep 30, 2024 $4.42M
Rd Expense Q3 2025 · Sep 30, 2024 $16.55M
Net Income Q3 2025 · Sep 30, 2025 −$51.15M
Net Income Q3 2025 · Sep 30, 2025 −$129.97M
Net Income Q3 2025 · Sep 30, 2024 −$19.13M
Net Income Q3 2025 · Sep 30, 2024 −$41.94M
Operating Income Q3 2025 · Sep 30, 2025 −$53.19M
Operating Income Q3 2025 · Sep 30, 2025 −$137.98M
Operating Income Q3 2025 · Sep 30, 2024 −$21.75M
Operating Income Q3 2025 · Sep 30, 2024 −$50.28M
Revenue Q3 2025 · Sep 30, 2025 $32.5M
Revenue Q3 2025 · Sep 30, 2025 $56.19M
Revenue Q3 2025 · Sep 30, 2024 $2.07M
Revenue Q3 2025 · Sep 30, 2024 $2.57M